Scholarlink

<p>Infections caused by pathogenic and antibiotic-resistant <i>Escherichia coli</i> are a major public health concern in both healthcare and livestock sectors. These bacteria are responsible for diseases such as urinary tract infections and gastroenteritis, which are increasingly difficult to treat with conventional antibiotics. The poultry industry, known for its extensive antibiotic use, serves as a significant reservoir for multidrug-resistant (MDR) <i>E. coli</i> strains. This study aimed to isolate and characterize lytic bacteriophages as an alternative therapeutic strategy against MDR <i>E. coli</i> from poultry. A total of 100 cloacal swab samples were collected from poultry farms in the Hazara Division, and geographic coordinates were recorded for each sampling site. Phage enrichment, purification, and host range testing were performed to identify effective bacteriophages against MDR isolates. Nineteen of the samples contained <i>E. coli</i> isolates, which exhibited high resistance to Ampicillin (94.7%) and Ceftazidime (89.4%) but remained susceptible to Norfloxacin (94.3%) and Cefoxitin (68.4%). Phage 64, a lytic bacteriophage, was successfully isolated from sewage water and showed inhibitory activity against MDR <i>E. coli</i> strains. Phage 64 demonstrated strong lytic activity with high thermal stability between 37&#xa0;°C and 50&#xa0;°C and optimal activity at pH 7.0. The burst size of Phage 64 was approximately 250 PFU/infected cell. The isolated phage 64 was tested against 19 <i>E. coli</i> isolates, wherein phage 64 exhibited potent lytic activity against 3 of them. The findings support the potential of bacteriophage therapy as an eco-friendly and sustainable alternative to antibiotics, aligning with the One Health framework by addressing antimicrobial resistance across human, animal, and environmental sectors. Future studies should focus on developing standardized protocols to assess the safety and in vivo therapeutic efficacy of bacteriophages. Bacteriophage therapy thus represents a promising and sustainable approach to control multidrug-resistant microorganisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Screening of bacteriophages for subsequent treatment of resistant Escherichia coli infections transmitted through poultry

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • Mobeen ur Rashid,
  • Saeed Ahmed,
  • Javed Muhammad,
  • Muhammad Tariq Navid,
  • Waseem Safdar,
  • Aman Karim,
  • Ijaz Ahmad,
  • Haider Ali,
  • Kashif Abdaal

摘要

Infections caused by pathogenic and antibiotic-resistant Escherichia coli are a major public health concern in both healthcare and livestock sectors. These bacteria are responsible for diseases such as urinary tract infections and gastroenteritis, which are increasingly difficult to treat with conventional antibiotics. The poultry industry, known for its extensive antibiotic use, serves as a significant reservoir for multidrug-resistant (MDR) E. coli strains. This study aimed to isolate and characterize lytic bacteriophages as an alternative therapeutic strategy against MDR E. coli from poultry. A total of 100 cloacal swab samples were collected from poultry farms in the Hazara Division, and geographic coordinates were recorded for each sampling site. Phage enrichment, purification, and host range testing were performed to identify effective bacteriophages against MDR isolates. Nineteen of the samples contained E. coli isolates, which exhibited high resistance to Ampicillin (94.7%) and Ceftazidime (89.4%) but remained susceptible to Norfloxacin (94.3%) and Cefoxitin (68.4%). Phage 64, a lytic bacteriophage, was successfully isolated from sewage water and showed inhibitory activity against MDR E. coli strains. Phage 64 demonstrated strong lytic activity with high thermal stability between 37 °C and 50 °C and optimal activity at pH 7.0. The burst size of Phage 64 was approximately 250 PFU/infected cell. The isolated phage 64 was tested against 19 E. coli isolates, wherein phage 64 exhibited potent lytic activity against 3 of them. The findings support the potential of bacteriophage therapy as an eco-friendly and sustainable alternative to antibiotics, aligning with the One Health framework by addressing antimicrobial resistance across human, animal, and environmental sectors. Future studies should focus on developing standardized protocols to assess the safety and in vivo therapeutic efficacy of bacteriophages. Bacteriophage therapy thus represents a promising and sustainable approach to control multidrug-resistant microorganisms.